Clinical trials: Population at Risk
Myocardial Ischemia, Rheumatic Diseases
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Ischemic heart disease (IHD) and its treatment carry profound public health and economic implications. Among Veterans, IHD represents one of the most common causes of death and disability, with over 500,000 affected individuals'…
- Trial name
- SEPPRMACI-ARM (NCT02694185)
- Testing
- Caplan IVR
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 5,269 people
- Sponsor
- VA Office of Research and Development
Alzheimers Disease
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in…
- Trial name
- GS1 (NCT02565511)
- Testing
- CAD106 Immunotherapy, CNP520, Alum
- Where
- 129 sites in United States, Australia and 8 more
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
Pneumococcal Disease
A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)
The purpose of this study is to determine if Pneumovax™ 23 (V110) is safe and immunogenic in participants from the Russian population who are 50 years of age and older or 2 to 49 years of age and at increased risk for…
- Trial name
- NCT01734239
- Testing
- Pneumovax™ 23
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Distress Syndrome in Premature Infant
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.
- Trial name
- NCT03969992
- Testing
- AeroFact, nCPAP
- Where
- 41 sites in United States, Canada
- Volunteers
- 261 people
- Sponsor
- Aerogen Pharma Limited
Gastric Cancer, Gastric Intestinal Metaplasia
Chemoprevention of Gastric Carcinogenesis
A clinical study of the efficacy of oral alpha-difluoromethylornithine (eflornithine or DFMO) in male and female subjects ages 30-60 with gastric premalignant lesions in two high risk regions of Latin America.
- Trial name
- NCT02794428
- Testing
- Eflornithine
- Where
- 2 sites in Honduras, Puerto Rico
- Volunteers
- 91 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Radiation dermatitis is experienced by almost all patients (up to 95%) receiving radiation therapy for cancer. Radiation dermatitis can be a serious condition because, in addition to its direct physical complications and the…
- Trial name
- NCT02142959
- Testing
- Omaveloxolone Lotion 0.5%, Omaveloxolone Lotion 3%, Vehicle Lotion
- Where
- 27 sites in United States
- Volunteers
- 187 people
- Sponsor
- Biogen
HIV Infections
Improving Treatment and Retention Adherence in Nontraditional Settings
This is a hybrid implementation-effectiveness study using both qualitative and quantitative methods. The research aims to examine whether providing a new, but approved, HIV once a month injection treatment…
- Trial name
- I-TRAINS (NCT04973254)
- Testing
- CAB-RPV LA, Standard treatment within an HIV clinic
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Boston Medical Center
Diabetes Mellitus, Type 2
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with…
- Trial name
- NCT01243424
- Testing
- linagliptin, glimepiride
- Where
- 613 sites in United States, Argentina and 41 more
- Volunteers
- 6,103 people
- Sponsor
- Boehringer Ingelheim